Massachusetts Financial Services Co. MA Increases Stock Position in IQVIA Holdings Inc. (NYSE:IQV)

Massachusetts Financial Services Co. MA raised its position in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.9% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 140,039 shares of the medical research company’s stock after buying an additional 2,576 shares during the quarter. Massachusetts Financial Services Co. MA owned about 0.08% of IQVIA worth $29,610,000 at the end of the most recent quarter.

Several other large investors have also recently modified their holdings of the stock. First Foundation Advisors raised its position in shares of IQVIA by 3.8% in the 2nd quarter. First Foundation Advisors now owns 1,161 shares of the medical research company’s stock worth $245,000 after purchasing an additional 43 shares during the last quarter. Team Hewins LLC raised its position in shares of IQVIA by 5.0% in the 1st quarter. Team Hewins LLC now owns 973 shares of the medical research company’s stock worth $246,000 after purchasing an additional 46 shares during the last quarter. Invera Wealth Advisors LLC raised its position in shares of IQVIA by 0.3% in the 2nd quarter. Invera Wealth Advisors LLC now owns 14,506 shares of the medical research company’s stock worth $3,183,000 after purchasing an additional 46 shares during the last quarter. Covestor Ltd raised its position in shares of IQVIA by 45.3% in the 1st quarter. Covestor Ltd now owns 154 shares of the medical research company’s stock worth $39,000 after purchasing an additional 48 shares during the last quarter. Finally, Oregon Public Employees Retirement Fund raised its position in shares of IQVIA by 0.3% in the 2nd quarter. Oregon Public Employees Retirement Fund now owns 15,668 shares of the medical research company’s stock worth $3,313,000 after purchasing an additional 48 shares during the last quarter. Hedge funds and other institutional investors own 89.62% of the company’s stock.

Insider Buying and Selling

In other IQVIA news, insider Eric Sherbet sold 1,300 shares of the business’s stock in a transaction on Tuesday, August 27th. The shares were sold at an average price of $246.33, for a total value of $320,229.00. Following the sale, the insider now owns 19,536 shares in the company, valued at approximately $4,812,302.88. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.60% of the stock is owned by company insiders.

IQVIA Trading Down 1.0 %

Shares of IQVIA stock opened at $242.24 on Friday. The company has a debt-to-equity ratio of 1.80, a quick ratio of 0.85 and a current ratio of 0.85. The company has a fifty day moving average of $240.60 and a 200 day moving average of $234.19. The company has a market capitalization of $44.16 billion, a P/E ratio of 33.09, a P/E/G ratio of 2.25 and a beta of 1.49. IQVIA Holdings Inc. has a fifty-two week low of $167.42 and a fifty-two week high of $261.73.

IQVIA (NYSE:IQV) last released its earnings results on Monday, July 22nd. The medical research company reported $2.64 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.57 by $0.07. IQVIA had a return on equity of 28.59% and a net margin of 9.39%. The firm had revenue of $3.81 billion during the quarter, compared to analysts’ expectations of $3.79 billion. During the same quarter last year, the business posted $2.22 earnings per share. The firm’s revenue was up 2.3% on a year-over-year basis. On average, sell-side analysts anticipate that IQVIA Holdings Inc. will post 10.25 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

IQV has been the subject of a number of recent analyst reports. Jefferies Financial Group lowered IQVIA from a “buy” rating to a “hold” rating and decreased their target price for the stock from $266.00 to $242.00 in a research report on Wednesday, July 24th. StockNews.com raised IQVIA from a “hold” rating to a “buy” rating in a research report on Thursday, September 5th. Morgan Stanley boosted their target price on IQVIA from $270.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 23rd. Royal Bank of Canada assumed coverage on IQVIA in a research note on Wednesday, September 4th. They set an “outperform” rating and a $275.00 price target for the company. Finally, UBS Group increased their price objective on shares of IQVIA from $295.00 to $300.00 and gave the stock a “buy” rating in a research note on Tuesday, July 23rd. Four analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $267.00.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.